Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Exploiting the hypoxia response.

Katie Binley1, On Kan, Jonathon White

  • 1Oxford BioMedica, Oxford Science Park, Oxford, OX4 4GA, UK.

Current Opinion in Molecular Therapeutics
|February 6, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rotational Atherectomy of Aorto-Ostial Calcification and Retained Native Leaflet to Facilitate Valve-in-Valve TAVI.

JACC. Case reports·2025
Same author

Gene therapy in children with AIPL1-associated severe retinal dystrophy: an open-label, first-in-human interventional study.

Lancet (London, England)·2025
Same author

Phase 1/2 AAV5-hRKp.RPGR (Botaretigene Sparoparvovec) Gene Therapy: Safety and Efficacy in RPGR-Associated X-Linked Retinitis Pigmentosa.

American journal of ophthalmology·2024
Same author

AAV-RPGR Gene Therapy Rescues Opsin Mislocalisation in a Human Retinal Organoid Model of <i>RPGR</i>-Associated X-Linked Retinitis Pigmentosa.

International journal of molecular sciences·2024
Same author

Impact of the COVID-19 Pandemic on Global TAVR Activity: The COVID-TAVI Study.

JACC. Cardiovascular interventions·2024
Same author

First-in-Human Gene Therapy Trial of AAV8-hCARp.hCNGB3 in Adults and Children With CNGB3-associated Achromatopsia.

American journal of ophthalmology·2023
Same journal

Gene therapy: Have the risks associated with viral vectors been solved?

Current opinion in molecular therapeutics·2011
Same journal

Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome.

Current opinion in molecular therapeutics·2010
Same journal

Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes.

Current opinion in molecular therapeutics·2010
Same journal

Corticorelin, a synthetic human corticotropin-releasing factor analog, for the treatment of peritumoral brain edema.

Current opinion in molecular therapeutics·2010
Same journal

Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma.

Current opinion in molecular therapeutics·2010
Same journal

Gevokizumab, an anti-IL-1β mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease.

Current opinion in molecular therapeutics·2010
See all related articles

Hypoxia, or low oxygen, is central to diseases like cancer. Understanding the hypoxia-signaling pathway has revealed new molecular therapies and gene therapy strategies for these conditions.

Area of Science:

  • Physiology
  • Molecular Biology
  • Medical Science

Background:

  • Hypoxia (low oxygen) is a critical factor in the pathology of major diseases such as cancer, cardiovascular disease, and retinopathy.
  • The hypoxia-signaling pathway actively influences gene expression, contributing to disease progression.

Purpose of the Study:

  • To review the elucidation of the hypoxia-signaling pathway.
  • To highlight the development of novel therapeutic strategies targeting this pathway.
  • To identify new therapeutic targets within the hypoxia-signaling pathway.

Main Methods:

  • Literature review focusing on hypoxia research.
  • Analysis of studies on gene expression regulation by hypoxia.
  • Examination of therapeutic strategies derived from hypoxia pathway research.

Related Experiment Videos

Main Results:

  • The hypoxia-signaling pathway is a crucial target for molecular therapies.
  • Elucidation of the pathway has led to advancements in physiologically targeted gene therapy.
  • Novel therapeutic targets within the hypoxia-signaling pathway have been identified.

Conclusions:

  • Targeting the hypoxia-signaling pathway offers promising therapeutic avenues for hypoxia-related diseases.
  • Further research into this pathway can yield innovative treatments for cancer, cardiovascular disease, and retinopathy.